FindTrial
Sign In

Study for the value of Mini PDX drug sensitivity test in the treatment of patients with malignant ascites

Study for the value of Mini PDX drug sensitivity test in the treatment of patients with malignant ascites

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONh-16009852
Enrollment
Unknown
Registered
2016-11-14
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant ascites

Interventions

Intraperitoneal perfusion chemotherapy group:Intraperitoneal perfusion chemotherapy

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients with pathological diagnosis of malignant ascites; 2. the expected survival time is greater than 3 months; 3. the patient or the client agreed to join the study, and to provide relevant personal information, such as ascites specimens for the study; 4. PKS score >60 points, the comprehensive evaluation of patients who are able to tolerate intraperitoneal chemotherapy.

Exclusion criteria

Exclusion criteria: 1. can not or refuse to provide tumor specimens, including ascites, etc.; 2. refused to accept the relevant treatment or follow-up programs.

Design outcomes

Primary

MeasureTime frame
Ascites subsided;—

Countries

China

Contacts

Public ContactXu Qing

Shanghai Tenth People's Hospital

xuqingmd@aliyun.com+86 13761325567

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026